Drug
Cobolimab clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 1
- first study started
- 2017
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
GlaxoSmithKline (3) · University of Hawaii (1) · Meghan Shea (1) · Tesaro, Inc. (1)
Often tested with
Tested in the same studies.
Dostarlimab (5) · Nelistotug (1) · Belrestotug (1) · Niraparib (1) · Bevacizumab (1)
Studies
Open first, then newest update. How each study uses cobolimab is read from its arms, and is right about nine times in ten.
Testing it · 6
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingPhase 2/3GlaxoSmithKlineNCT04655976Written as Cobolimab
- TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruitingPhase 2University of HawaiiNCT03680508Written as TSR-022 and TSR-042
- Dostarlimab and Cobolimab in Advanced Cervical CancerActive, not recruitingPhase 2Meghan SheaNCT06238635Written as Cobolimab
- Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042CompletedPhase 1Tesaro, Inc.NCT03307785Written as TSR-022
- A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerActive, not recruitingPhase 1/2GlaxoSmithKlineNCT06521567Written as Cobolimab
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT04446351Written as Cobolimab
Given in every arm · 2 — cobolimab is usual care beside what is tested
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingPhase 1Tesaro, Inc.NCT02817633Written as TSR-022
- Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)CompletedPhase 1GlaxoSmithKlineNCT02723955Written as Cobolimab
Codes
What other systems call cobolimab · ClinicalTrials.gg INT014687
- UNII (FDA) 3K5H4TX2KPCOBOLIMABOne source FDA
- NCI Thesaurus C128627CobolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3K5H4TX2KP | COBOLIMAB | One source FDA |
| NCI Thesaurus | C128627 | Cobolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.